Shilpa Medicare Limited's 100% subsidiary, Shilpa Pharma Lifesciences Limited received certificate of suitability (CEP) from EDQM (European Directorate for the Quality of Medicines & Healthcare) for API, Desmopressin.
Desmopressin is synthetic peptide manufactured by Shilpa Pharma Lifesciences through solid phase synthesis. Desmopressin helps to reduce frequent urination and excessive thirst. This is used to treat central diabetes insipidus and bedwetting.
"We at Shilpa have always been investing in challenging chemical synthesis. With unwavering commitment and belief in our technical capabilities, we have invested in developing a versatile peptide portfolio over past few years and Desmopressin is the first peptide molecule to receive CEP from the European Regulators. This CEP showcases our proficiency in quality-oriented development as well as commercial manufacturing capabilities that meet the expectations of global quality standards paving way for more such products to follow", said Mr. Keshav Bhutada, Executive Director- Shilpa Pharma Lifesciences Limited.
Shares of Shilpa Medicare Limited was last trading in BSE at Rs. 834.65 as compared to the previous close of Rs. 813.45. The total number of shares traded during the day was 19870 in over 1355 trades.
The stock hit an intraday high of Rs. 838.85 and intraday low of 805.70. The net turnover during the day was Rs. 16321930.00. |
